|
|
|
|
The basic profile of the BKG Pharma compound:
- Most Frontrunners are metabolites of existing non-antibiotic drugs used for decades
- New classes of antimicrobials
- Potent against multi-resistant bacteria despite their resistance mechanisms
- Synergistic effect in combination with common classic antibiotics
- Reversal of resistance to common antibiotics
- Difficult to induce resistance in bacteria against the New Classes of Compounds
- Oral, i.v, i.m, topical administration
- Extensive market potential
- Broad target profile
- Easy and inexpensive to synthesize
- Efficacious in key animal models at doses < NOAEL
|
|
